A B S T R A C T
Background. Relatively little is known about the role of phosphatidylserine (PS) in procoagulant activity (PCA) in patients with diabetic kidney disease (DKD). This study was designed to evaluate whether exposed PS on microparticles (MPs) and MP-origin cells were involved in the hypercoagulability in DKD patients. Methods. DKD patients (n ¼ 90) were divided into three groups based on urinary albumin excretion rate, defined as normoalbuminuria (No-A) (<30 mg/24 h), microalbuminuria (Mi-A) (30-299 mg/24 h) or macroalbuminuria (Ma-A) (>300 mg/24 h), and compared with healthy controls (n ¼ 30). Lactadherin was used to quantify PS exposure on MPs and their original cells. Healthy blood cells (BCs) and human umbilical vein endothelial cells (HUVECs) were treated with 25, 5 or 2.5 mmol/L glucose as well as 3-12 mg/dL uric acid and cells were evaluated by clotting time and purified coagulation complex assays. Fibrin production was determined by turbidity. PS exposure and fibrin strands were observed using confocal microscopy. Results. Using flow cytometry, we found that PS þ MPs (derived from platelets, erythrocytes, HUVECs, neutrophils, monocytes and lymphocytes) and BCs were significantly higher in patients than in controls. Furthermore, the number of PS þ MPs and BCs in patients with Ma-A was significantly higher than in patients with No-A. Similarly, we observed markedly elevated PS exposure on HUVECs cultured with serum from patients with Ma-A versus serum from patients with Mi-A or normoalbuminuria. In addition, circulating PS þ MPs cooperated with PS þ cells, contributing to markedly shortened coagulation time and dramatically increased FXa/thrombin generation and fibrin formation in each DKD group. Confocal microscopy images demonstrated colocalization of fibrin with PS on HUVECs. Moreover, blockade of exposed PS on MPs and cells with lactadherin inhibited PCA by $80%. In vitro, BCs and endothelial cells exposed more PS in hypoglycemia or hyperglycemia. Interestingly, reconstitution experiments showed that hypoglycemia-treated cells could be further activated or injured when recovery is obtained reaching hyperglycemia. Moreover, uric acid induced PS exposure on cells (excluding platelets) at concentrations >6 mg/dL. Linear regression analysis showed that levels of PS þ BCs and microparticles were positively correlated with uric acid and proteinuria, but negatively correlated with glomerular filtration rate.
Conclusions. Our results suggest that PS
þ MPs and MP-origin cells play procoagulant roles in patients with DKD. Blockade of PS could become a novel therapeutic modality for the prevention of thrombosis in these patients.
Keywords: cells, diabetic kidney disease, fibrin, microparticles, procoagulant activity
I N T R O D U C T I O N
Patients with diabetes mellitus (DM) are considered to be prothrombotic with major disturbances in hemostasis associated with an increased risk of venous thromboembolism, especially when microvascular complications of DM occur, such as diabetic kidney disease (DKD) [1, 2] . However, patients with DKD do not receive routine antithrombotic therapy. Therefore, study on the coagulation mechanism and therapeutic target of DKD is necessary.
Phosphatidylserine (PS) is a phospholipid that is abundant in eukaryotic plasma inner membranes, and exposed by the action of scramblase on the cell's surface in biological processes such as apoptosis and cell activation [3] . During these processes, microparticles (MPs) are released from the cell membrane having exposed PS and expressing membrane antigens specific to their origin [4] . PS on cells and MPs creates a catalytic surface for blood-clotting factors, facilitating the conversion of prothrombin to thrombin [5] . This accelerates coagulation activation in patients, causing complications such as venous thrombosis due to diabetes, nephrotic syndrome and polycythemia [6] [7] [8] . However, whether PS exposure on cells and MPs contributes to hypercoagulability in patients with DKD has not been investigated. While elevated uric acid (UA) levels can be a consequence of impaired renal function [9] , the effect of UA on PS exposure has not been evaluated. Additionally, previous studies have reported that MPs derived from monocytes, platelets (PLTs) and endothelial cells (ECs) are elevated in DKD [10] [11] [12] . However, procoagulant activity (PCA) of MPs was not determined, nor were MPs from other cells included in their studies.
Lactadherin, a PS-binding glycoprotein, is secreted by macrophages and contains two lectin-type C domains that are homologous to the blood-clotting factors V and VIII C domains [13] . We have recently reported that lactadherin is as a more sensitive probe for the detection of PS þ cells or MPs and a more efficient blocker of PS compared with annexin V [14] . Therefore, in the present study, we used lactadherin to measure the exposure of PS on blood cells (BCs)/ECs/MPs and evaluate their relevance to PCA in DKD. Our results provide several novel findings regarding the pivotal role of PS in thrombosis in DKD.
M A T E R I A L S A N D M E T H O D S

Patients
Ninety Type 2 diabetic patients with DKD who were admitted to the First Hospital of Harbin Medical University during the period November 2015-February 2016 were evaluated. The diagnosis of Type 2 DM was based on World Health Organization criteria [15] . The statistics of diabetes medication were based on the last 3 months as the glycosylated hemoglobin (HbA1c) reflect blood glucose level of 8-12 weeks. Renal status was based on albumin excretion rate (AER) measurements in two out of three consecutive urine collections and defined as normal AER (<30 mg/24 h), microalbuminuria (Mi-A) (30-299 mg/24 h) or macroalbuminuria (Ma-A) (>300 mg/24 h). Patients with Type 1 DM; urinary tract infection; urolithiasis; end-stage renal disease (undergoing dialysis or having received a kidney transplant); malignant or systemic disease; iron, folic acid and vitamin B12 deficiency; blood transfusion within the past 6 months; uncontrolled hypertension; active or chronic infection or other known renal diseases; or use of any drug known to affect hemostasis were excluded on the basis of interview. Thirty healthy subjects were included as parallel controls. The study was approved by local ethics committee of Harbin Medical University.
Reagents
Human umbilical vein endothelial cells (HUVECs), EC medium and poly-L-lysine were from ScienCell (San Diego, CA, USA). Calibrated polystyrene latex beads (1.0 lm) were from Sigma (Gillingham, UK). Trucount Tube (Cat. No. 340334), Annexin V, propidium iodide (PI), purified CD235a (clone GA-R2), CD31 (clone L133.1), CD41a (clone HIP8), CD45 (clone 2D1), CD66b (clone G10F5), CD14 (clone M5E2), CD3 (clone 1F4), CD142 (clone HFT-1) and mouse IgG1/IgG2a (clone X40/ X39) were from Becton Dickinson Biosciences (San Jose, CA, USA). All monoclonal antibodies were labeled in our laboratory with Alexa Fluor 647 or Alexa Fluor 488 (Invitrogen, Eugene, OR, USA). Alexa Fluor 488 or Alexa Fluor 647-conjugated lactadherin and fluorescein-labeled fibrinogen were prepared in our laboratory. Human factors Va, VIIa, IXa, X, Xa, prothrombin, thrombin, fluorescein Glu-Gly-Arg-chloromethylketone (EGRchloromethylketone) and biotinylated EGR-chloromethylketone were all from Haematologic Technologies (Burlington, VT, USA). Recombinant human factor VIII was from American Diagnostica Inc. (Stamford, CT, USA). Mouse anti-fibrin II b chain (clone NYBT2G1) was from Accurate Chemical & Scientific (Westbury, NY, USA). Fluorescein-maleimide, fluorescein isothiocyanate phalloidin, 4',6-diamidino-2-phenylindole (DAPI), Alexa Fluor 647-labeled isotype-matched control antibody were from Molecular Probes (Invitrogen). Percoll was from GE Healthcare (Uppsala, Sweden). Tyrode's buffer containing 1 mm Hepes was from our laboratory and was filtered through a 0.22 mm syringe filter from Millipore (Watford, UK). Chromogenic substrates S-2765 and S-2238 were from Instrumentation Laboratory Company (Bedford, MA, USA).
Protein purification and labeling
Bovine lactadherin was purified as previously described, and was labeled with Alexa Fluor 488 or Alexa Fluor 647 according to the package instructions. The ratio of fluorescein to lactadherin was 1.2/1 and 1.1/1, respectively [16] .
Preparation of circulating BCs and MPs
Fresh whole blood was collected in the morning after 12 h of fasting using a 21-gauge needle and drawn into a blood collection tube containing 3.2% sodium citrate. Erythrocytes [red blood cells (RBCs)] and platelet-rich plasma (PRP) were prepared within 30 min after blood collection by centrifugation for 13 min at 200 g at room temperature. To acquire PLT-free plasma (PFP), 1000 mL PRP was centrifuged for 20 min at 1500 g at room temperature. For MP-depleted plasma (MDP) preparation, 700 mL of supernatant PFP was centrifuged for 45 min at 20 000 g at 20 C, and 1/10 of bottom layer was MPs. White blood cells (WBCs) were obtained through density gradient centrifugation with Percoll. A gradient was prepared using 2 mL 30% Percoll layered on top of 2 mL 68% Percoll. The WBC-rich layer was collected and transferred to the gradient tube. After centrifugation at 400 g for 20 min, a cellular band, enriched in WBC, was visible at the interface. WBCs were then washed twice before use.
Effect of medium with different glucose on BCs from healthy subjects
PLTs, WBCs and RBCs from healthy subjects were cultured in medium with different concentrations of glucose (2.5, 5 or 25 mmol/L). PLTs (10 6 cells/mL) were suspended in Tyrode's buffer and treated with glucose for 1 h [17] . WBCs (10 6 cells/ mL) were incubated in RPMI-1640 medium containing glucose for 2 h [18] . RBCs were suspended to a final hematocrit of 10% in phosphate buffer saline (PBS) containing varying concentrations of glucose (2.5, 5, 25 mmol/L) for 48 h at 37 C [19] . In another set of experiments, after incubation for the indicated time in hypoglycemic media, cells were harvested and washed with PBS and then incubated with high glucose or normal glucose as mentioned above. At prescribed time points, cells were analyzed for PS exposure.
HUVECs culture and reconstitution experiments
We evaluated the effect of glucose and plasma of DKD patients on ECs. ECs (ScienCell) were cultured in EC medium at 37 C in a 5% CO 2 humidified atmosphere and incubated in growth media containing 2.5, 5, 25 mmol/L glucose for 2 h or 20% of pooled serum obtained from 10 patients of each group or healthy donors at room temperature for 48 h. In another set of experiments, after incubation with 2.5 mmol/L glucose for 2 h, ECs were harvested and washed with Endothelial Cell Growth Medium-2 (EGM-2) medium and then incubated in growth media containing 5 or 25 mmol/L glucose for 2 h.
Effect of UA on PS exposure on HUVECs and BCs from healthy subjects UA powder was dissolved in a 1 mol/L NaOH solution, and then the UA solution was added to the medium at final concentrations of 0, 3, 6, 9 or 12 mg/dL, at a pH 7.2-7.4. ECs were cultured in EC medium at 37 C in a 5% CO 2 humidified atmosphere and incubated with different concentrations of UA for 24 h [20] . PRP samples from healthy individuals were treated with different concentrations of UA for 30 min [21] . WBCs (10 6 cells/mL) were incubated in RPMI-1640 medium containing different concentrations of UA for 30 min at 37 C [22] . RBCs were incubated in vitro at a hematocrit of 0.4% in Ringer solution with the indicated concentrations of UA for 24 h [23] .
Flow cytometric analysis MPs phenotype
MPs were identified as previously reported [7] . RBC-, PLT-, WBC-(including neutrophil, lymphocyte, monocyte) and ECderived MPs were defined as <1 mm, lactadherin þ and either
þ CD41a À , respectively. MPs exposing tissue factor (TF) were identified as those with expression of CD142. The number of each MP type per microlitre was calculated by Trucount Tube (with a precise number of fluorescent beads (48 678) to determine the number of MPs in a sample) after accumulation of 10 000 gated events.
Flow cytometric analysis of PS exposure on BCs and HUVECs
PS exposure on BCs and ECs was quantified by flow cytometry based on the binding of lactadherin. BCs or ECs suspended in Tyrode's buffer were adjusted to 0.5-1 Â 10 6 /mL. Then 5 mL Alexa Fluor 488-conjugated lactadherin was added to the cell suspension and incubated for 10 min at room temperature in the dark. Ten thousand events per sample were acquired and analyzed with BD FACSDiva Software.
Coagulation time and inhibition assays
PCA of MPs and MP-origin cells was evaluated by one-stage recalcification time assay in a KC4A-coagulometer (Amelung, Labcon, Heppenheim, Germany). MP-containing suspensions (10 mL of MP-enriched suspension was resuspended in 90 mL Tyrode's buffer) or 100 mL of RBCs ( C. The reaction was stopped by addition of Ethylenediaminetetraacetic acid (EDTA) at a final concentration of 7 mm. After the addition of 10 mL S-2765 (0.8 mm) to each reaction, the quantity of FXa formed was determined immediately at 405 nm in kinetic mode on a Universal Microplate Spectrophotometer (PowerWave XS; Bio-Tek, Winooski, VT, USA). Results were evaluated against the rate of substrate cleavage of a standard dilution of FXa. Measurement of extrinsic FXa formation was analogous to that for intrinsic FXa except that cells were incubation with 130 nm FX, 1 nm FVIIa and 5 mm Ca 2þ . For the prothrombinase assay, cells were incubated with 1 nm FVa, 0.05 nm FXa, 1 mm prothrombin and 5 mm Ca 2þ in prothrombinase buffer for 5 min at 25 C. EDTA and S-2238 were added to each microplate, and thrombin production was assessed as previously described [19] . Inhibition assays of coagulation complexes by lactadherin were performed as follows. Each kind of cell was incubated with 128 nm lactadherin for 10 min at 25 C in Tyrode's buffer. The quantity of thrombin or FXa formation was then assessed as above.
Fibrin formation assays
Fibrin formation was quantified by turbidity as described [24] . Briefly, isolated MPs/BCs were added to recalcified
Increases of PS exposure in DKD (10 mm, final) MDP (88% MDP, final) in the presence or absence of 128 nm lactadherin. Fibrin production was measured by turbidity at 405 nm in a SpectraMax 340PC plate reader.
Confocal microscopy
Confocal microscopy was used to localize PS on the different cell types. PLTs/WBCs/RBCs from Ma-A DKD (macro-DKD) patients and ECs cultured with macro-DKD serum were incubated with Alexa Fluor 488-lactadherin (4 nm, final concentration) for 10 min at room temperature in the dark. Cells were then washed to remove unbound dye, and imaged immediately. Observation of PS exposure on PLTs was carried out as previously described [7] . For in vitro fibrin generation experiments, ECs cultured on 1% gelatin-coated coverslips chamber with 20% pooled DKD or normal serum for 24 h were rinsed with Tyrode's buffer. Rinsed ECs were then overlaid with prewarmed MDP (15%) in the presence of 3 mm calcium. Fibrin networks were imaged using laser confocal microscopy in the presence of Alexa Fluor 647-conjugated anti-fibrin antibody. Background signal was calculated using a similarly labeled isotype-matched control antibody. Cells and nuclei were visualized by actin staining with fluorescein isothiocyanatephalloidin (1 mg/mL) and DAPI (4 0 , 6-diamidino-2-phenylindole; 300 nm), respectively.
Fibrin formation was measured by turbidity at 405 nm in a SpectraMax 340PC plate reader.
Statistical analysis
Numerical variables were tested for normal distribution with the Kolmogorov-Smirnov test. Data are expressed as mean 6 SD, and statistical analysis was made by t-test or analysis of variance (ANOVA) as appropriate. Categorical variables were compared using the v 2 -test. P < 0.05 was considered statistically significant.
R E S U L T S
Subject characteristics
The clinical characteristics of the patients stratified by DKD status are given in Table 1 . Patients with DKD were older and had a longer duration of diabetes. DKD patients had higher HbA1c, fasting glucose, blood urea nitrogen (BUN) and lower glomerular filtration rate (GFR) than healthy controls. Although the levels of HbA1c of our patients seemed to be mildly increased, this could reflect the severity of DKD. Previous study has identified that the most appropriate risk thresholds for HbA1c in DM were 6.5% for microvascular disease [25] . Every 1% higher mean HbA1c level above these 
-A, defined as a urinary albumin/creatinine ratio of >33.9 mg albumin/mmol creatinine, or doubling of the serum creatinine level to at least 200 lmol/L, the need for renalreplacement therapy or death due to renal disease) [25] . Moreover, the RBC counts of patients were significantly lower than those of healthy controls. There was a significant increase trend in coagulation index across the three study groups. The mean fibrinogen and D-dimer were highest in the Ma-A group.
Number and origin of MPs in DKD
PS
þ MPs in patients were higher than controls ( Figure 1A ).
We further analyzed cellular origins of MPs. MPs derived from PLTs (PMPs), RBCs (RMPs), neutrophils (NMPs), lymphocytes (LMPs) and monocytes (MMPs), as well as from endothelial cells (EMPs), were all significantly increased in the patients compared with controls (P < 0.05 for all) ( Figure 1B-G) . Few MPs with coexpression of both PS and TF could be identified in patients or controls ( Figure 1H ). 
Measurement of PS
þ BCs in DKD PS þ BCs in each group were quantified by flow cytometry and localized with confocal microscopy. The mean percentages of PS þ BCs in patients were significantly higher than those in healthy subjects (P < 0.05 with control). To observe PS on the outer membrane of cells, PLTs/RBCs/WBCs samples from a healthy subject and a macro-DKD patient were incubated with Alexa Fluor 488-lactadherin or PI (for WBC) and imaged on a confocal laser scanning microscope. As shown in Figure 2B and D, almost no staining by lactadherin could be detected on PLTs, RBCs and WBCs membranes in healthy subjects, whereas lactadherin binding on PLTs accompanying vesiculation formation ( Figure 2C ) and RBCs ( Figure 2E )/WBCs ( Figure 2F ) indicated PS exposure in patients. These results further confirmed that there is increased PS exposure on BCs in DKD patients.
The relationships between PS þ BCs/MPs and proteinuria, UA, HbA1c or GFR were analyzed ( Table 2) . We found proteinuria had a significant positive correlation with the levels of PS, except for PS þ RBCs. UA had a positive correlation with the levels of PS, and HbA1c had positive correlations with PS þ RBCs/PLTs/monocytes (MNCs)/neutrophils (PMNs)/MPs. GFR had negative correlations with PS þ BCs/MPs, except for PS þ lymphocytes.
Hypo-and hyperglycemia affect exposure of PS on cells
The percentages of PS þ cells were measured to assess the effect of normo-(5 mmol/L), hypo-(2.5 mmol/L) and hyperglycemica (25 mmol/L) on BCs and ECs. Analysis of the results clearly indicated that both hypoglycemia and hyperglycemia resulted in significantly increased PS expression at both time points when compared with normoglycemia. As shown in Figure 3A (left and middle panel), hypo-and hyperglycemia induced a significantly increase in PS exposure on PLTs at 30 min, compared with controls. PS þ WBCs and ECs were elevated at 1 h under the tested exposure conditions ( Figure 3B and C, left and middle panel). Similar effects were observed under these conditions resulting in a pronounced increase in PS exposure on RBCs at 24 h ( Figure 3D , left and middle panel). Data are displayed as mean 6 SD. BCs and ECs subjected to hypoglycemia showed a modest increase in PS exposure, but cells undergoing hypoglycemia followed by a subsequent hyperglycemia showed a more pronounced increase in PS exposure (right panels of Figure 3A 9 .8% versus 12.4%, 3B 20.1% versus 23.9%, 3C 6.1% versus 8.2%, 3D 5.7% versus 3.8%). However, we found that PS exposure on hypoglycemia-treated cells was somewhat reversible when recovering in normoglycemia (right panels of Figure 3A 5.5%, 3B 14.6%, 3C 3.7%, 3D 1.4%), though the PS exposure remained higher than baseline over the time period tested. . After a longer exposure of 24 h, PS exposure increased to 5.6% (P < 0.05) and 6.8% (P < 0.05) on ECs exposed to 9 and 12 mg/dL UA, # P < 0.01; *P < 0.05. PS exposure on BCs was observed by confocal microscopy. PLT, RBC and WBC of controls and macro-DKD patients were incubated with Alexa Fluro 488-lactadherin and PI in the dark for 10 min at room temperature. Cells were then washed very gently to remove unbound dye. Cell membrane displayed green fluorescence when labeled with lactadherin and nucleus displayed red fluorescence. Lactadherin staining (green) is observed on PLT membrane (arrow head) (C) and RBC (E)/WBC (F insert) (arrow head) in DKD patients but no staining in controls (B, D). The inset bar equals 5 lm. 
respectively ( Figure 4D , # P < 0.05 versus control). However, we found no difference in PS expression on PLTs when incubated with UA at 30 min compared with control ( Figure 4B ).
PS exposure on ECs cultured with serum from DKD patients
To mimic the in vivo conditions in DKD, ECs were cultured with normal or DKD serum for 48 h. We also observed the PS exposure on ECs under confocal laser-scanning microscope. As shown in Figure 5B , ECs with normal serum were visualized by actin and DAPI. However, most ECs cultured in macro-DKD sera for 48 h retracted from the cell-cell junctions; filopodia and localized regions on the cell margins were stained with lactadherin ( Figure 5C ).
PCA of BCs, ECs and MPs in DKD
To investigate the relationship of PS externalization to hypercoagulable state in DKD patients, PCA of cultured ECs, BCs and MPs from healthy individuals or patients was assessed by recalcification-time assays. The results showed that with identical numbers of RBCs/PLTs/WBCs and equal volumes of PS exposure on cells cultured with hypo-or hyperglycemia were significantly higher than on cells cultured with normoglycemia (left, middle). We also showed the kinetic change of PS exposure on cells (right). PS exposure on BCs and ECs were further increased when recovery from hypoglycemia is obtained reaching hyperglycemia. In contrast, PS exposure on cells were reversal when recovery is obtained reaching normoglycemia, though still higher than the baseline. Data are displayed as mean 6 SD.
Increases of PS exposure in DKD MPs, the CT was significantly reduced in patients, compared with controls with shorter CT in Ma-A than in Mi-A or No-A. ECs treated with each DKD serum also showed increased PCA compared with controls ( Figure 6A , # P < 0.01, *P < 0.05). In order to explore the contribution of PS and TF to the PCA of BCs, ECs and MPs in patients, we performed coagulation inhibition assays. PS and TF were blocked with lactadherin and anti-TF antibody, respectively. PCA of BCs/MPs of macro-DKD patients and ECs cultured with macro-DKD serum was almost entirely inhibited by 128 nm lactadherin, whereas 26.5 mg/mL anti-TF did not affect the CT significantly ( Figure 6B , # P < 0.01). We further investigated the PCA of BCs, ECs and MPs using intrinsic, extrinsic FXa and prothrombinase assays (Figure 7) . The production of the three procoagulant enzyme complexes was increased in the DKD groups compared with controls, and higher in Ma-A than in Mi-A or No-A ( Figure 7A , # P < 0.01, *P < 0.05). Serum of each DKD group both increased the production of procoagulant enzyme complexes of ECs ( Figure 7C , # P < 0.01, *P < 0.05). To determine the necessity of exposed PS and TF on BCs, ECs or MPs to support procoagulant reactions, inhibition studies were also performed with lactadherin and anti-TF body. For each kind of cell, 128 nm lactadherin blocked production of the three procoagulant enzyme complexes up to over 85%, while anti-TF showed little effect ( Figure 7B and D) .
Fibrin deposition and formation assays
Fibrin is important in thrombosis in DKD, so we assessed whether fibrin production of MPs and MP-origin cells was increased in DKD patients. The production of fibrin on RBCs, . Different concentrations of UA had no effect on PS exposure on PLTs at 30 min (B). UA induced PS exposure on WBCs at concentrations >6 mg/dL at 30 min (C). UA induced PS exposure on ECs at concentrations >9 mg/dL at 24 h (D). Data are displayed as mean 6 SD.
# P < 0.05 versus control.
FIGURE 5: PS exposure and reconstitution experiments of cultured ECs. ECs were cultured in medium with serum from different stages DKD patients and healthy subjects for 48 h, respectively. And we used lactadherine-488 to detect the PS exposure at every 12 points (A) (*P < 0.01 versus control, # P < 0.05 versus No-A, **P < 0.05 versus Mi-A). ECs were cultured with normal serum for 48 h and visualized by actin and DAPI (B). ECs cultured for 48 h with macro-DKD serum were stained with CD31-Alexa Fluor 647 and PS exposure was detected using lactadherin-Alexa Fluor 488 and visualized using confocal microscopy, and found that ECs with macro-DKD serum led to retraction of cell margins, extension of filopods (arrow head), release of endothelial-MPs (arrow head) and lactadherin (green) binding on filopods and MPs (arrow) (C). . Experiments were also performed using 2 Â 10 4 ECs cultured for 48 h in each DKD serum or normal serum (C). Intrinsic FXa formation was measured in the presence of FIXa, FVIII and thrombin. Extrinsic FXa production was assessed in the presence of FVIIa. Thrombin generation was investigated in the presence of FXa and FVa.
# P < 0.01; *P < 0.05. The capacity of 128 nm lactadherin to block procoagulant enzyme complexes on MPs and their related cells from macro-DKD patients was evaluated. In each kind of cell, lactadherin decreased activity of the procoagulant enzyme complexes by !85% (B, D). Data are displayed as mean 6 SD.
# P < 0.01versus Ma-A group or anti-TF group, respectively. CT and inhibition assay. CT of MPs and MP-associated BCs or serum cultured ECs from healthy subjects and DKD patients were evaluate. MPs and MP-associated cells have more PCA than those from healthy donors (A). PCA of blood cells from macro-DKD patients and macro-DKD serum-cultured ECs was detected in the presence of lactadherin (128 nM) or 40 lg/mL anti-TF. Lactadherin entirely inhibited PCA induced by cells, while anti-TF has little effect (B). Data are displayed as mean 6 SD. # P < 0.01; *P < 0.05.
Increases of PS exposure in DKD PLTs, WBCs and MPs increased steadily from baseline and peaked at different time points, and the final level of fibrin in patients were higher than healthy controls. In addition, the production of fibrin in patients with Ma-A was higher than patients with Mi-A or No-A (Figure 8A-D) . Meanwhile, ECs cultured with serum of each DKD patients also significantly shortened the onset and increased the production of fibrin compared with healthy controls ( Figure 8E ). However, this fibrin formation was blocked when lactadherin was included in the plasma ( Figure 8A -E). These data indicate that MPs and MP-origin cells trigger PS-dependent fibrin production in DKD. We used confocal microscopy to observe whether PS exposure on macro-DKD serum cultured-ECs relates directly to local PCA. As shown in Figure 8F , most ECs in DKD serum retracted from the cell-cell junctions, while the filopodia and localized regions on the cell margins stained brightly with lactadherin. Meanwhile large fibrin strands were radially distributed along filopodia of DKD serum-cultured ECs. We further , leukocytes (C), MPs (D) and cultured ECs (E) in healthy subjects or DKD patients in the absence or presence of 128 nm lactadherin. Fibrin polymerization was monitored by turbidity at 405 nm. MPs/cells from DKD patients supported more fibrin generation than those from healthy subjects. Lactadherin reduced fibrin generation, which was lower than control. We used confocal microscopy to observe the fibrin deposition around cultured ECs. Most ECs in DKD serum retracted from the cell-cell junctions, while the filopodia and localized regions on the cell margins stained brightly with lactadherin; meanwhile, large fibrin strands were radially distributed along filopodia of DKD serum-cultured ECs (arrow head) (F). We further confirmed that the fibrin production in the presence of PS. PS (arrow head) (green) and fibrin (arrow head) (red) have coherent distributions that overlap (arrow) (yellow) around ECs (G). Additionally, MPs were shedding from cultured ECs and present in the injury gap.
confirmed the fibrin production in the presence of PS, for as shown in Figure 8G , PS (green) and fibrin (red) have coherent distributions that overlap (yellow) around ECs. Additionally, MPs were shedding from cultured ECs and present in the injury gap ( Figure 8F and G).
D I S C U S S I O N
In this study, we have shown that DKD patients live in a state of chronic BC and EC activation or injury, associated with increased MP release and PS exposure, in which hyper-, hypoglycemia and UA play important roles. Second, increased numbers of PS þ MPs, BCs and ECs resulted in shortened CT and higher levels of FXa, thrombin and fibrin. Third, we showed that lactadherin could lengthen CT and decrease FXa, thrombin and fibrin formation, which further confirmed the role of PS in mediating PCA. Lastly, we observed that PS exposed on ECs incubated with DKD serum supports fibrin formation highlighting the prothrombotic role of PS-driven PCA in DKD.
We found that DKD patients have a higher level of MPs than healthy subjects, which may be due to numerous factors, such as hyperglycemia, dyslipidemia and oxidative stress [26] . A previous study showed that diabetic patients with nephropathy displayed elevated numbers of MPs originating from PLTs and ECs, consistent with our findings [27] . However, in contrast to our results, another study showed that the number of PMPs and EMPs in Type 2 diabetic patients were similar to those of healthy donors [28] . Differences in both patients and control population recruitment and/or in MP analysis may account for this discrepancy. Moreover, we showed for the first time that PS-positive MPs significantly increased, and consequently contributed to hypercoagulability in the patients with DKD by providing catalytic sites for factor tenase and prothrombinase complex formation. In this study, we found that the TF þ MPs have relatively little effect on the PCA of DKD, which is consistent with Diamant et al. showing that TFpositive MPs are associated with components of the metabolic syndrome but not with coagulation [29] .
Our results found that the percentage of PS exposure on BCs progressively increased with albuminuria. Previous studies showed that patients with DKD have higher levels of activated PLTs and leukocytes, supporting our results [11, 30] . The absolute numbers of PS þ RBC in DKD patients are higher than those in healthy subjects despite DKD patients having lower RBC counts. This may partly due to renal function deficiencyrelated anemia [31, 32] . In addition, we found that both hyperglycemia (25 mmol/L) and hypoglycemia (2.5 mmol/L) induced increased PS exposure on cells compared with normoglycemia (5 mmol/L). Previous study indicated that hypoglycemia may induce hematologic changes and stimulate stress responses that are associated with cells damage, supporting our results [33] . Interestingly, we found that when hypoglycemia is followed by hyperglycemia, the effects of previous hypoglycemia are further worsened, whereas when recovery from hypoglycemia is obtained by reaching normoglycemia, the deleterious effects of the previous hypoglycemia are partly counterbalanced. This finding is consistent with the evidence reported in cells and animals [34, 35] , suggesting that hyperglycemia after hypoglycemia produces a 'reperfusion-like' effect [36] . In our opinion, it is interesting that even in the presence of normoglycemia, the effects of hypoglycemia linger, suggesting that hypoglycemia might produce a sort of legacy effect for multiple hours. These results indicated that cells could be activated or injured under these conditions that occur frequently during DKD [37] , and suggesting that in clinical practice, a gradual correction of blood glucose in patients with hypoglycemia may be preferred to a more rapid correction resulting in hyperglycemia. We also found that high UA concentration could induce PS exposure on BCs, except for PLTs, which is consistent with a previous study which showed that different concentrations of UA did not affect PMPs levels in an in vitro experiment using PRP of healthy persons [21] . Many studies have identified that hyperuricemia was an independent risk factor for the development of DKD [38, 39] . Our results prompted us to hypothesize that increase the expression of PS on cells may be one of the potential mechanisms by which UA mediates DKD. Previous study has shown that PS þ PLT-associated PCA was elevated in chronic kidney disease [40] . Our results confirm this and further test the PCA of other cells types, such as leukocytes and ECs. We further performed PS inhibition assays and proved that exposed PS supports the assembly of prothrombinase, leading to generation of FXa/thrombin and formation of fibrin. We believe further studies are necessary to evaluate coagulation of podocyte and podocyte-derived MPs in DKD, as Burger et al. have indicated that podocyte-derived MPs are generated in response to high glucose in vitro [41] .
Dysfunction of vascular endothelium is considered a critical event for the progression of DKD [42] . We revealed a significant increase in the proportion of EMPs in the macro-DKD group and a mild increase in the micro-DKD group compared with the normal-DKD group, which indicates the existence of ECs dysfunction in DKD patients. Kessler et al. reported that increased levels of von Willebrand factor in patients with Type 2 diabetes were positively correlated with glomerular injury, supporting our results [43] . Moreover, PS exposure on ECs induced by hyper/hypoglycemia and UA was demonstrated in experimental conditions mimicking the in vivo conditions, suggesting that this effect could be clinically relevant. High glucose was able to induce PS externalization on ECs, consistent with reports that hyperglycemia impaired the integrity of endothelial glycocalyx [44] . Another study showed that UA could induce aging and death of human ECs by local activation of oxidative stress [20] . Our data further shows that PS on ECs surface provides membrane-binding sites for FVa/FXa (data not shown) and support for prothrombinase complex assembly, thrombin generation and fibrin deposition. More importantly, our confocal images demonstrate for the first time, fibrin formation at site of PS exposure, suggesting that ECs may be directly related to local coagulation activation via PS activity. A previous study has suggested that glomerular ECs are closely aligned to HUVECs [45] . Therefore, though we used HUVECs in the present study, it seems reasonable to speculate that PS þ glomerular capillary ECs provide a scaffold that brings clotting factor together, resulting in fibrin formation at sites of damage. The shrinking of ECs causing the increase in intercellular spaces shown on our confocal microscopy may result in increased permeability of glomerular filtration membrane and induce proteinuria. Elevated levels of ICAM-1 and P-selectin on ECs in DKD [46] may be associated with the homing of PS þ leukocytes, PLTs and RBCs in glomeruli, and further increase local fibrin formation. Taken together, it is likely that PS þ MPs, BCs and ECs provide links between blood and intraglomerular coagulation.
Our present data suggest that PS exposure on MPs and MPorigin cells is associated with the coagulation cascade and may contribute to renal hypercoagulation. Moreover, our linear regression analysis showed that levels of PS þ BCs and MPs were positively correlated with UA and proteinuria, but negatively correlated with GFR. In addition, we previously indicated that PS þ cells/MPs also increased the level of FXa, thrombin, fibrin and shortened the CT of IgA nephrolathy and are related to renal fibrin deposition [47] . These results indicated that PS þ cells and MPs likely support thrombosis in the renal vasculature and result in renal dysfunction and disease progression. Thus, prevention of thrombosis during the course of DKD development is important. Our results demonstrate that PS provides binding sites for FXa and prothrombinase complexes and promotes thrombin formation. Previous results showed that administration of an oral FXa inhibitor in a mouse model of DKD resolved diabetic glomerulosclerosis [48] . This study together with our study have shown that directly targeting FXa and prothrombinase complexes might decrease thrombotic and renal disease risk. Future research should focus on discovery and deployment of direct PS inhibitors.
Previous study indicated that monocytes are the main source of TF in DKD, and play an important role in the hypercoagulation of diabetes and DKD [49] . However, coagulation and inhibition assays in our study indicated that PS þ cell/MPs seem to be the main source of coagulation in DKD. One possible explanation for this discrepancy is that plasma-exposed TF is frequently encrypted with little or no detectable PCA and is decrypted through the availability of clusters of PS [50] . Moreover, our finding is also supported by our previous studies showing that the expression of activated TF overlaps with PS exposure and TF-dependent FXa generation was decreased after blocking PS [7] . Previous studies of a diabetic mouse model demonstrated that fibrin localized in glomeruli did not contain increased TF staining [51] , supporting our results.
In summary, we illustrate that hypercoagulability in DKD patients is associated with increasing levels of MPs and injured BCs and ECs, in which abnormal glucose during the hypoglycemic therapy and high UA concentration may play important roles. Moreover, our findings suggest that PS exposure on MPs and cells has a procoagulant and prothrombotic role in the patients. PS inhibition assays using lactadherin suggest that blockage of PS might constitute a novel therapeutic way for preventing thrombosis, which needs to be investigated in future clinical trials.
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